Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Animal models, particularly mouse models, play a central role in the study of the etiology, prevention, and treatment of human prostate cancer. While tissue culture models are extremely useful in understanding the biology of prostate cancer, they cannot recapitulate the complex cellular interactions within the tumor microenvironment that play a key role in cancer initiation and progression. The National Cancer Institute (NCI) Mouse Models of Human Cancers Consortium convened a group of human and veterinary pathologists to review the current animal models of prostate cancer and make recommendations about the pathologic analysis of these models. More than 40 different models with 439 samples were reviewed, including genetically engineered mouse models, xenograft, rat, and canine models. Numerous relevant models have been developed over the past 15 years, and each approach has strengths and weaknesses. Analysis of multiple genetically engineered models has shown that reactive stroma formation is present in all the models developing invasive carcinomas. In addition, numerous models with multiple genetic alterations display aggressive phenotypes characterized by sarcomatoid carcinomas and metastases, which is presumably a histologic manifestation of epithelial-mesenchymal transition. The significant progress in development of improved models of prostate cancer has already accelerated our understanding of the complex biology of prostate cancer and promises to enhance development of new approaches to prevention, detection, and treatment of this common malignancy.

[1]  C. Abate-Shen,et al.  Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic , 2013, Cancer and Metastasis Reviews.

[2]  R. Cardiff,et al.  B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. , 2012, Cancer research.

[3]  Paul G. Hynes,et al.  TMPRSS2- Driven ERG Expression In Vivo Increases Self-Renewal and Maintains Expression in a Castration Resistant Subpopulation , 2012, PloS one.

[4]  S. Yeh,et al.  Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines , 2012, EMBO molecular medicine.

[5]  C. Magi-Galluzzi,et al.  Intraductal carcinoma of the prostate. , 2012, Archives of pathology & laboratory medicine.

[6]  Gerald C. Chu,et al.  Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases , 2012, Cell.

[7]  L. Tran,et al.  Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. , 2012, Cancer research.

[8]  M. Ittmann,et al.  Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. , 2012, Cancer cell.

[9]  Jeffrey M. Rosen,et al.  Activation of Wnt Signaling by Chemically Induced Dimerization of LRP5 Disrupts Cellular Homeostasis , 2012, PloS one.

[10]  S. Abdulkadir,et al.  A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53 , 2011, Oncogene.

[11]  D. Tuveson,et al.  SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. , 2011, The Journal of clinical investigation.

[12]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[13]  J. McKenney,et al.  Conditional Expression of the Androgen Receptor Induces Oncogenic Transformation of the Mouse Prostate* , 2011, The Journal of Biological Chemistry.

[14]  R. M. Simpson,et al.  Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. , 2011, The American journal of pathology.

[15]  M. Henry,et al.  Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? , 2011, Nature Reviews Urology.

[16]  L. Tran,et al.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. , 2011, Cancer cell.

[17]  Chris Sander,et al.  MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors , 2011, PloS one.

[18]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[19]  R. Matusik,et al.  Wnt/β-Catenin activation promotes prostate tumor progression in a mouse model , 2010, Oncogene.

[20]  P. Scardino,et al.  Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. , 2011, The American journal of pathology.

[21]  Fen Wang.  Modeling human prostate cancer in genetically engineered mice. , 2011, Progress in molecular biology and translational science.

[22]  M. Poutanen,et al.  Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. , 2010, Neoplasia.

[23]  Yuzhuo Wang,et al.  Development of metastatic and non‐metastatic tumor lines from a patient's prostate cancer specimen—identification of a small subpopulation with metastatic potential in the primary tumor , 2010, The Prostate.

[24]  Peter S. Nelson,et al.  The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment , 2010, PloS one.

[25]  Jiaoti Huang,et al.  Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.

[26]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[27]  R. Cardiff,et al.  Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. , 2010, Cancer cell.

[28]  M. Karin,et al.  B-cell-derived lymphotoxin promotes castration-resistant prostate cancer , 2010, Nature.

[29]  C. Bieberich,et al.  MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells , 2010, PloS one.

[30]  P. Russell,et al.  Modeling prostate cancer: a perspective on transgenic mouse models , 2010, Cancer and Metastasis Reviews.

[31]  J. Cuzick,et al.  SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. , 2010, Cancer research.

[32]  S. Hayward,et al.  Functional Remodeling of Benign Human Prostatic Tissues In Vivo by Spontaneously Immortalized Progenitor and Intermediate Cells , 2009, Stem cells.

[33]  S. Hirschfeld,et al.  Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer Patients , 2009, Clinical Cancer Research.

[34]  M. Teitell,et al.  ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.

[35]  D. Wilson.  Tissue , 2009, The Lancet.

[36]  N. Northrup,et al.  Prostate cancer in dogs: comparative and clinical aspects. , 2009, Veterinary journal.

[37]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[38]  R. de Wit,et al.  Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer , 2008, British Journal of Cancer.

[39]  G. V. van Leenders,et al.  Histopathological and immunohistochemical characterization of canine prostate cancer , 2008, The Prostate.

[40]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[41]  F. Yang,et al.  Fibroblast growth factor-2 mediates transforming growth factor-β action in prostate cancer reactive stroma , 2008, Oncogene.

[42]  M. Teitell,et al.  Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. , 2007, Cancer cell.

[43]  Leif E. Peterson,et al.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. , 2007, Cancer cell.

[44]  J. Resau,et al.  Inactivation of Apc in the mouse prostate causes prostate carcinoma. , 2007, Cancer research.

[45]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[46]  M. Ather,et al.  Neuroendocrine differentiation in prostate cancer. , 2006, Urology.

[47]  I. Mellinghoff,et al.  Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Nelson,et al.  The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. , 2006, Cancer research.

[49]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[50]  R. Cardiff,et al.  Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. , 2005, Cancer research.

[51]  Feng Yang,et al.  Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. , 2005, Cancer research.

[52]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[53]  Yuzhuo Wang,et al.  Development and characterization of efficient xenograft models for benign and malignant human prostate tissue , 2005, The Prostate.

[54]  M. Ittmann,et al.  The role of fibroblast growth factors and their receptors in prostate cancer. , 2004, Endocrine-related cancer.

[55]  O. Klezovitch,et al.  Hepsin promotes prostate cancer progression and metastasis. , 2004, Cancer cell.

[56]  M. Rubin,et al.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.

[57]  M. Ittmann,et al.  Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia , 2004, The Prostate.

[58]  M. Ittmann,et al.  Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. , 2003, Cancer research.

[59]  M. Ittmann,et al.  Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. , 2003, Cancer research.

[60]  P. Scardino,et al.  Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  Mustafa Ozen,et al.  Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. , 2003, Cancer research.

[62]  Leif E. Peterson,et al.  Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. , 2003, Cancer research.

[63]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[64]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[65]  Todd R. Golub,et al.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[66]  R. Vessella,et al.  LuCaP 35: A new model of prostate cancer progression to androgen independence , 2003, The Prostate.

[67]  Satoru Takahashi,et al.  Age‐dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: Lack of influence of carcinogen or testosterone treatment , 2003, Cancer science.

[68]  Jose J. Galvez,et al.  Prostatic intraepithelial neoplasia in genetically engineered mice. , 2002, The American journal of pathology.

[69]  G. Ayala,et al.  Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. , 2002, Cancer research.

[70]  S. Hayward,et al.  Malignant transformation in a nontumorigenic human prostatic epithelial cell line. , 2001, Cancer research.

[71]  K. Imaida,et al.  Experimental prostate carcinogenesis - rodent models. , 2000, Mutation research.

[72]  M. Ittmann,et al.  Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[74]  R. Dahiya,et al.  Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. , 1998, Differentiation; research in biological diversity.

[75]  R. Maronpot,et al.  Spontaneous Lesions in Aging FVB/N Mice , 1996, Toxicologic pathology.